-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewNet Present Value Model: Zynerba Pharmaceuticals Inc’s Zygel
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2735 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Obesity Drug Details: VK-2735 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: VK-2735...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Idiopathic Pulmonary Fibrosis Drug Details: AD-214 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-161 in Influenzavirus B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-161 in Influenzavirus B Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BNT-161 in Influenzavirus B Infections Drug Details:BNT-161 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-0214 in Adrenomyeloneuropathy (AMN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-0214 in Adrenomyeloneuropathy (AMN) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VK-0214 in Adrenomyeloneuropathy (AMN)Drug Details: VK-0214 (formerly MB-10866) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2735 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: VK-2735 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paclitaxel in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Paclitaxel in Non-Small Cell Lung Cancer Drug Details: Paclitaxel (FID-007) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-5211 in Bone Fracture
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-5211 in Bone Fracture report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VK-5211 in Bone FractureDrug Details:VK-5211 (LGD-4033) is under development for the treatment of...